Rapid Nexus Deploys Advanced Wound Tech to VA, DoD Healthcare Systems

BREA, Calif. – April 29, 2026 – California-based medical technology company Rapid Nexus Nanotech Wound Solutions, Inc. has secured major supply contracts with the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD), initiating the first large-scale commercial deployment of its FDA-cleared wound treatment, Hemastyl®. Beginning May 1, the technology will be introduced into two of the nation's largest integrated healthcare systems, targeting the complex and often debilitating wounds common among military service members and veterans.

The deployment marks a pivotal transition for Rapid Nexus, moving its innovative technology from clinical validation into widespread, real-world use. Clinical training is set to commence across VA and DoD facilities, providing a direct channel to patients and allowing the company to gather performance data at an unprecedented scale.

A New Front in a Long Battle

The VA and DoD healthcare systems are on the front lines of a constant battle against severe and chronic wounds. Military personnel often sustain complex traumatic injuries from blasts and combat, which are frequently contaminated and resist conventional healing. For the nation's aging veteran population, chronic conditions like diabetes lead to a high prevalence of diabetic foot ulcers, which are notoriously difficult to treat and a leading cause of lower-limb amputations.

For decades, the standard of care for these wounds has primarily focused on management: cleaning, debriding, covering, and protecting the injury site. While advanced dressings, negative pressure therapies, and even hyperbaric oxygen have improved outcomes, many treatments still only address surface-level symptoms, leaving the underlying biological failures unresolved. This often leads to a frustrating cycle of stalled healing, infection, and repeated hospitalizations.

Hemastyl® enters this challenging landscape with a fundamentally different approach. The topical treatment is designed not just to manage a wound, but to actively improve the biological environment and support the body's own repair mechanisms.

This new option is a welcome development for providers and partners working within these systems. "We're working with wounded service members and veterans who face some of the most complex wounds in medicine," said Steve Clark of Recon Supply, the service-disabled veteran-owned small business partnering with Rapid Nexus for distribution. "For years, providers have had very few options beyond managing these cases. Introducing a new treatment into VA and DoD systems is a meaningful step toward changing that."

Rewriting the Biology of Healing

The core innovation of Hemastyl® lies in its ability to orchestrate a coordinated healing response at the cellular level. Instead of providing a single growth factor or simply creating a moist barrier, the technology is engineered to support the physiological conditions necessary for tissue stability and recovery.

A recent peer-reviewed preclinical study in a diabetic mouse model provides a window into this mechanism. Researchers observed that the treatment simultaneously activated multiple, distinct repair processes in the tissue surrounding the wound. This included angiogenesis (the formation of new blood vessels), nerve signaling and regeneration, a modulated immune response, and tissue rebuilding.

This multi-pathway activation stands in stark contrast to most existing therapies, which typically target a single biological pathway. The study showed dozens of biological signals turning on in a coordinated pattern, a signature associated with the body shifting from a chronic, non-healing state into an active state of repair. The findings were highly statistically significant (p = 0.00217), indicating an extremely low probability that the results occurred by chance. In a field where changing a single biomarker is often considered a success, the simultaneous activation of numerous repair pathways suggests a powerful and comprehensive biological response.

"This is an important step as we move from research and regulatory milestones into expanded real-world clinical use," stated Dr. Margaret Kalmeta, founder and chief scientific officer of Rapid Nexus. "We are continuing to build both the clinical and biological evidence supporting this approach while expanding access to patients who have lived with non-healing wounds for years."

A Strategic Path to Market

Rapid Nexus's entry into the VA and DoD systems is more than a clinical milestone; it is a masterclass in business strategy for the competitive medtech sector. By securing these government contracts, the company has established a direct and efficient path to commercialization, bypassing many of the reimbursement challenges and market access hurdles that can stall new technologies.

The federal government is a massive purchaser of medical supplies, with the DoD and civilian departments spending a combined $8.2 billion in fiscal year 2021. The procurement processes, governed by strict regulations like the VA's Federal Supply Schedule (FSS) and the DoD's Distribution and Pricing Agreement (DAPA), are complex. However, they offer a direct route to a high volume of patients with a significant unmet need.

The partnership with Recon Supply is a key component of this strategy. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), Recon Supply provides a crucial advantage. Federal acquisition regulations, including the "Vets-First Rule of Two" statute, create powerful incentives for the government to contract with veteran-owned businesses. This relationship not only facilitates access but also aligns the company’s mission with the communities it aims to serve.

This direct-to-government model allows Rapid Nexus to generate revenue and gather extensive real-world evidence while simultaneously pursuing a longer-term strategy for broader market applications. It provides a stable foundation from which to challenge established players in the advanced wound care market, many of whom focus on different mechanisms of action.

Beyond the Battlefield: The Future of Tissue Repair

The deployment of Hemastyl® for acute and complex wounds within the VA and DoD is just the first phase of Rapid Nexus’s broader vision. The company is actively pursuing the FDA's breakthrough device designation pathway for its technology platform, including Hemastyl® and a related product, NerveStim™, for chronic wound and neuropathy-related indications.

The Breakthrough Device Program is designed to expedite the development and review of technologies that offer more effective treatment for life-threatening or irreversibly debilitating conditions. Achieving this designation would signal that the FDA recognizes the technology's potential to provide a significant advantage over existing therapies, particularly for the millions suffering from chronic, non-healing wounds complicated by nerve damage.

This dual-track strategy—near-term commercialization in a high-need government market combined with a long-term push into the larger chronic care space—showcases a sophisticated approach to growth. The data and clinical experience gained from the VA and DoD deployment will be invaluable in supporting the company's regulatory submissions for expanded indications. By proving its value in treating some of the toughest wounds, Rapid Nexus is building a powerful case for its technology's potential to transform care across the entire spectrum of tissue repair.